🔎 Trials Near Me

Akèy › Myelom Miltip › Indiana › Indianapolis

Etid klinik pou Myelom Miltip nan Indianapolis, IN

13 etid pou Myelom Miltip ap chèche patisipan nan sit nan ak bò kote Indianapolis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Ap rekriteFaz 3
  • Franciscan Health, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Ap rekriteFaz 4
  • Indiana University, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Ap rekriteFaz 2
  • Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535

Collection of Tissue Samples for Cancer Research

Ap rekriteEtid obsèvasyon
  • Indiana University - Purdue, Indianapolis
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Ap rekriteFaz 3
  • Community Health Network, Inc., Indianapolis
  • Community Health Network, Inc., Indianapolis
  • Community Health Network, Inc., Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06152575

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Ap rekriteFaz 3
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • IU Health Methodist Hospital, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Ap rekriteFaz 1
  • Indiana University, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Ap rekriteFaz 2
  • Indiana University Health, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07284758

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Ap rekriteFaz 1
  • Franciscan St. Francis Health /ID# 280928, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Ap rekriteFaz 1
  • Indiana University Health Simon Cancer Center, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT05137054

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Ap rekriteFaz 1/2
  • Community Health Network, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04068597

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Ap rekriteFaz 3
  • Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
  • Saint Catherine Hospital, Indianapolis
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387

The Indiana Myeloma Registry

Ap rekriteEtid obsèvasyon
  • Indiana University Simon Cancer Center, Indianapolis
Laj 18 ak plis · Tout sèks · Mizajou Nov 10, 2025 · NCT03616483

Etid Myelom Miltip nan lòt vil

Lòt etid nan Indianapolis

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.